Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "T2DM" Clear all
Completed Not applicable Interventional Results available

Point-of-Care Glucose Testing and Insulin Supplementation

NCT01702311
View directory record Official record
Conditions
Diabetes
Interventions
Bedtime insulin Aspart (Novolog)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program

NCT01030978
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Bright Bodies Healthy Lifestyle Program, Control
Behavioral
Lead sponsor
Yale University
Other
Eligibility
11 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

NCT01107717
View directory record Official record
Conditions
Diabetes
Interventions
metformin\pioglitazone\exenatide, metformin, glyburide and glargine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Enhancing Self-Management Support in Diabetes Through Patient Engagement

NCT02834923
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Enhanced Engagement Protocol for CTH (EE-CTH), Connection to Health (CTH)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY3025876 in Participants With Diabetes

NCT01870297
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY3025876, Placebo, Liraglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chula Vista, California • Orange, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 23, 2026, 10:35 PM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intraluminal Imaging of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes

NCT02688920
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
EUS and OCT imaging
Procedure
Lead sponsor
Victoria Gomez
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 23, 2026, 10:35 PM EDT
Completed No phase listed Observational

Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors

NCT05048108
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 23, 2026, 10:35 PM EDT
Enrolling by invitation Not applicable Interventional

To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years

NCT07387393
View directory record Official record
Conditions
Cardiometabolic Conditions, Hypertension (HTN), Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus (T2DM), Overweight (BMI > 25), Weight Loss Trial
Interventions
PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

NCT05562063
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release

NCT05287906
View directory record Official record
Conditions
Overweight and Obesity, Type 2 Diabetes Mellitus
Interventions
Water, Glucose, Steviol Glycosides, Steviol Glycosides plus glucose, Rebaudioside A
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Miami Gardens, Florida • Naples, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

NCT01555008
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
LX4211, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
6
States / cities
Anniston, Alabama • Chula Vista, California • Edgewater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 23, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Weight Changes During and After Pregnancy in Women With Gestational Diabetes

NCT02388958
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

NCT00542009
View directory record Official record
Conditions
Weight Management, Treatment Of Obesity
Interventions
CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD, Placebo, CE-326,597 5mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • National City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Raspberries and Postprandial Metabolism

NCT03403582
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Raspberries
Other
Lead sponsor
Oklahoma State University
Other
Eligibility
21 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Mindfulness: a Novel Approach for the Management of Diabetes-related Distress

NCT01805245
View directory record Official record
Conditions
Emotional Distress, Type 2 Diabetes, Stress
Interventions
Mindfulness Based Stress Reduction
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Strengthening, Engaging, and Empowering Dyads Through Nutrition & Wellness

NCT06473129
View directory record Official record
Conditions
Diabetes, Memory Impairment
Interventions
Food for Life Culinary Workshops
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Not listed Not applicable Interventional

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

NCT02487888
View directory record Official record
Conditions
Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
Interventions
Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
Other
Lead sponsor
Proove Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Beverly Hills, California • Fresno, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Home Food Delivery for Diabetes Management in Patients of Rural Clinics

NCT04876053
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diet, Healthy
Interventions
Healthy Food Delivery Intervention, CDCES Consultation Only
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
13
States / cities
Batesville, Arkansas • Corning, Arkansas • Eureka Springs, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 23, 2026, 10:35 PM EDT
Active, not recruiting Not applicable Interventional

Virtual Diabetes Group Visits Across Health Systems

NCT06094491
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus), Hypertension, Heart Disease Chronic, Stroke, Hyperlipidemias, Peripheral Vascular Diseases, Obesity
Interventions
Virtual Group Visit
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Orland Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 23, 2026, 10:35 PM EDT